Clinical study affirms efficacy of SIRT with SIR-Spheres microspheres
New clinical research has highlighted the benefits of treating metastatic colorectal cancer with SIR-SPheres microspheres.
A large multi-centre clinical study has re-affirmed that Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres is safe and effective in patients with metastatic colorectal cancer.
SIR-Spheres microspheres are fully pre-market approved by the Food and Drug Administration as a form of radiation therapy for colorectal liver metastases. They are used either alone or alongside systemic chemotherapy and are usually administered via the hepatic artery, which supplies blood to the liver.
The new studies aimed to evaluate the overall survival rates of patients and tumour response to using this type of therapy, specifically in patients who are no longer responding to chemotherapy.
Dr Andrew Kennedy, director of radiation and oncology research at the Sarah Cannon Research Institute in Nashville, Tennessee, and lead investigator, explained that patients in the study had long histories of pre-treatment. He said: "These research findings should help to further define the role of SIRT in helping to shrink or control the tumors and prolong patient survival."
The researchers reported median survival rates of 13, nine and eight months in patients who had received one, two or three prior lines of chemotherapy. There were also no significant differences in adverse affects, prompting them to conclude that SIRT with SIR-Spheres microspheres provides a "favourable risk/benefit ratio" in patients who have failed chemotherapy for metastatic colorectal cancer.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance